250
Participants
Start Date
June 18, 2024
Primary Completion Date
August 24, 2027
Study Completion Date
August 24, 2031
cemacabtagene ansegedleucel
An allogeneic CAR T cell therapy targeting CD19
Fludarabine
Chemotherapy for lymphodepletion
Cyclophosphamide
Chemotherapy for lymphodepletion
Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for LBCL.
RECRUITING
Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
Medical Oncology Hematology Consultants, Newark
RECRUITING
MedStar Georgetown University Hospital, Washington D.C.
RECRUITING
The Center for Cancer and Blood Disorders, Bethesda
RECRUITING
Virginia Cancer Specialists, Fairfax
RECRUITING
University of Virginia, Charlottesville
RECRUITING
Virginia Oncology Associates - Norfolk, Norfolk
RECRUITING
Duke Blood Cancer Center, Durham
RECRUITING
Novant Health Cancer Institute- Hematology, Charlotte
RECRUITING
Augusta University Georgia Cancer Center, Augusta
RECRUITING
Advent Health Cancer Institute, Orlando
RECRUITING
Miami Cancer Institute at Baptist Health, Inc., Miami
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Vanderbilt University Medical Center, Nashville
RECRUITING
University of Louisville Health Brown Cancer Center, Louisville
RECRUITING
Norton Cancer Institute, Louisville
RECRUITING
University of Kentucky Medical Center, Lexington
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Oncology Hematology Care - Kenwood, Cincinnati
RECRUITING
University of Cincinnati Medical Center, Cincinnati
RECRUITING
Indiana Blood and Marrow Transplantation, Indianapolis
RECRUITING
Rush University Medical Center, Chicago
RECRUITING
Washington University School of Medicine - Siteman Cancer Center, St Louis
RECRUITING
University of Missouri - Ellis Fischel Cancer Center, Columbia
RECRUITING
The University of Kansas Hospital, Kansas City
RECRUITING
Texas Oncology - Dallas Fort Worth, Dallas
RECRUITING
Texas Oncology - Tyler, Tyler
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Texas Transplant Institute, San Antonio
RECRUITING
Texas Oncology - Central South, Austin
RECRUITING
Rocky Mountain Cancer Centers, Denver
RECRUITING
Huntsman Cancer Institute, University of Utah, Salt Lake City
RECRUITING
Intermountain Health LDS Hospital, Salt Lake City
RECRUITING
Banner MD Anderson Cancer Center, Gilbert
RECRUITING
Cedars-Sinai Medical Center, Los Angeles
RECRUITING
University of California, Los Angeles, Los Angeles
RECRUITING
City of Hope, Duarte
RECRUITING
University of California, Davis Comprehensive Cancer Center, Sacramento
RECRUITING
University of California, San Diego, San Diego
RECRUITING
University of California, San Francisco, San Francisco
RECRUITING
Alta Bates Summit Medical Center, Berkeley
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
Oncology Associates of Oregon, Eugene
RECRUITING
Fred Hutchinson Cancer Center, Seattle
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
Astera Cancer Care, East Brunswick
RECRUITING
John Theurer Cancer Center, Hackensack
RECRUITING
Rutgers Cancer Institute of New Jersey, New Brunswick
RECRUITING
Queen Elizabeth II Health Sciences Centre, Halifax
RECRUITING
Princess Margaret Cancer Centre - University Health Network, Toronto
RECRUITING
Hopital de'L'Enfant-Jesus, Québec
Lead Sponsor
Collaborators (1)
Foresight Diagnostics, Inc.
UNKNOWN
Allogene Therapeutics
INDUSTRY